Company Presentation

Partnered Discovery

Of High-Quality

Antibody Drug Candidates

2

AbCheck’s Unique Offering

A unique source of human antibodies with one of

the industry's most versatile technology platforms

Pure partnered-discovery provider

Antibodies with biological function

Provider of exclusive sequences

Antibodies for therapeutic application

3

Corporate Overview

Founded in 2009 as top

partner for antibody

discovery and

optimization

A reliable source in the

identification of novel,

medically relevant

antibodies against any

target using one of the

industry's most versatile

technology platforms,

validated through several

products in the clinic

High-quality, high-value

antibodies based on

cutting-edge in vitro and

in vivo techniques, that

integrates antibody

screening and

optimization platforms

Only provider of

rabbit mass

humanization

Microfluidics platform

tailored for high-

throughput functional

agonist antibody

identification

4

AbCheck Corporate Background

EXPERIENCE IN DISCOVERY PLATFORMS THROUGH

Leadership with substantial expertise in the

biopharmaceutical industry

AbCheck is a fully-owned subsidiary of Affimed

(Nasdaq: AFMD)

Validation through several clinical programs

USA-based business development and marketing

division

4

Dr. Volker LangManaging Director

Dr. Vera MolkenthinChief Scientist

Dr. Oleh PetrivVP New Technology

5

Our Current Track Record

Over 40 Successful Antibody Discovery Projects

6

Application: Immune Checkpoints

• Antibodies targeting Immune Checkpoints

are powerful immuno-activators and have

shown impressive results in various cancer

indications

• AbCheck has identified anti-checkpoint IgGs

with in vivo activity using its AbSieve®

technology

7

Application: Opportunity in Advancing Therapeutic Area

• New therapeutic approaches on the rise that

use antibodies or fragments as components

• Technology platform is particularly well suited

to deliver single-chain variable fragments

as targeting elements rapidly

• AbCheck’s Naïve Human Library has

delivered highly specific scFv with affinities in

the single digit nanomolar range Chimeric Antigen

Receptor (CAR)

8

Application: MHC Peptide Complexes

• MHC complexes display intracellular peptides

on the surface of cells and alert the immune

system to ongoing tumorigenic processes

inside a cell

• Antibodies specifically targeting MHC-peptide

complexes open up the therapeutic drug

target space to otherwise unattainable tumor-

specific cytosolic proteins

• AbCheck isolated peptide-specific antibodies

against MHC complexes in a pilot study

9

AbCheck’s Commitment to Meeting Industry Demands

Industry Needs AbCheck’s Solution

Desire to identify specific antibodies

with high developability potential

Desire to use in vivo generated antibodies

and humanize them consistently

Desire to work in final drug format

Desire to optimize drug-like properties

of antibody candidates

Desire to find rare antibodies with special

functions

Naïve Human Libraries

Mass Humanization

AbSieve®

AbAccel®

Microfluidics Functional Sorting & Binding

Technology

Suite

Naïve Human Libraries Mass Humanization

AbSieve®AbAccel®

Microfluidics

Functional Sorting &

Binding

11

Microfluidics- Functional Sorting

Addressing special

epitope requirements

and specific biological

functions

De novo discovery of

antibodies with agonistic

properties, for example

against GPCR targets

Using microfluidics-based

functional assays in ultra-

high throughput

AbCheck´s unique

functional sorting

technology

Fastest and most efficient way to isolate antibodies

with therapeutically relevant biological functions

12

Microfluidics- Functional Sorting Principle

13

Microfluidics- Binding

Induction of immune

responses in chicken

or rabbit

Detection of rare mAb clones

using recombinant antigens

on beads or overexpressed

targets on cells

• The high-throughput droplets microfluidics method finds rare antibody clones to even difficult targets

14

Naïve Human Libraries

Human sequences Largest structural

diversity

Deliver high affinity

and highly specific

antibodies requiring

no optimization

Low

immunogenicity

by nature

Used by AbCheck

since 2010 with

proven and

robust

performance

Ideal for CAR-T cell projects

15

Rabbit Mass Humanization

Uses CDR3 of

immunized rabbits

Human frameworks and

germlined CDRs

Combining the power

of in vivo immunization

with the best of in vitro

engineering and in silico

computational optimization

Special potential

for difficult targets

Immunized Libraries Computational Design In Vitro Selection

A novel approach to human antibody discovery

16

• AbCheck’s Rabbit Mass Humanization delivers antibodies that are 90% identical to human germline

Rabbit Mass Humanization

17

AbSieve®

Recommended for

selections of IgG

and bi-specifics

Screening in final

drug formatTarget

specific

VH/VL poolsYeast

Display

IgG (bivalent)

Bi-specific formats

Any other

formats

AbSieve® avoids drop-outs due to reformatting

Next generation Yeast Display for advanced selection potential

18

AbAccel®

Premium

Optimization Method

Quality Maintains beneficial

antibody properties

Multi-factor antibody

optimization in a single process

• To meet special affinity

requirements

• To improve developability

Based on a proprietary

algorithm

Upgrade and final polishing

before development

AbAccel®

High-End lead optimization

19

• Optimizes affinity while preserving other drug-

relevant properties

• AbAccel® repeatedly achieved two logs

improvement in affinity with optimal species

cross-reactivity and thermal stability

• It includes a complete permutation of 50 CDR

positions according to a defined library design

AbAccel®

20

Integrated Customer Project

Partnered Discovery of High-quality Antibody Drug Candidates

21

Integrated Process Approach for Projects at AbCheck

Client AbCheck/Joint Project Team Client

Antigen Lead candidate discovery Exclusive antibody

sequence for drug

development

Antibody profile Milestone achievement

Define research milestones Weekly communication

Data and IP transfer

Client specifications

for target &

lead antibodies

Joint project team

defining project

objectives and work plan

Work progressed

at AbCheck with

weekly updates

Leads returned

to client for further

development

22

Tailor Made Workflows

Human Antibody Libraries• scFv, IgG or other format

• Naïve or immunized repertoires

• QC tested

Antigen• Purified protein

• Expression cell lines

Phage Panning/Sorting• Parallel selection approaches

• Cell panning

• Epitope-focused selection

• Species Cross-reactivity

Deep screen• Single colony lysates

• ELISA/Flow Cytometry

• Thermal stability

• Functional assays

Confirmed Leads• Binding & specificity validation

• BIACORE™

• Cell-based assays

• Functional assays

Verified Hits• Bacterial/eukaryotic re-cloning

• scFv, IgG or other format

• Sequencing & purification

Detailed project plans including milestones

are defined in a joint project teamWeekly updates ensure maximal transparency

Transfer of VH/VL sequences to customer

23

One of the most versatile therapeutic antibody platforms

that provides a customizable way to your lead candidate

Accessible through a pure

partnered-discovery model

Successfully validated platform

• AbCheck antibodies already in clinical

and preclinical development

Experts in:

• Antibody discovery

• Lead optimization & humanization

Seeking more partners for drug discovery and

novel technology to add further capabilities